No Data
No Data
BioAge Stock Advances 14% On Novartis Research Collaboration
BioAge Labs Says It Is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
Morgan Stanley Downgrades BioAge Labs to Underweight From Overweight, Slashes Price Target to $5 From $40
Unlock the Full List